Membrane‐bound CD95 ligand modulates CD19‐mediated B cell receptor signaling and EBV activation

Abstract

AbstractPost‐transplant lymphoproliferative disorders (PTLDs) are associated with Epstein‐Barr virus (EBV) infection in transplant recipients. Most of lymphoblastoid cell lines (LCLs) derived from EBV‐immortalized B cells or PTLDs are sensitive to CD95‐mediated apoptosis and cytotoxic T cell (CTL) killing. CD95 ligand (CD95L) exists as a transmembrane ligand (mCD95L) or a soluble form (sCD95L). Using recombinant mCD95L and sCD95L, we observed that sCD95L does not affect LCLs. While high expression of mCD95L in CTLs promotes apoptosis of LCLs, low expression induces clathrin‐dependent CD19 internalization, caspase‐dependent CD19 cleavage, and proteasomal/lysosomal‐dependent CD19 degradation. The CD95L/CD95‐mediated CD19 degradation impairs B cell receptor (BCR) signaling and inhibits BCR‐mediated EBV activation. Interestingly, although inhibition of the caspase activity restores CD19 expression and CD19‐mediated BCR activation, it fails to rescue BCR‐mediated EBV lytic gene expression. EBV‐specific CTLs engineered to overexpress mCD95L exhibit a stronger killing activity against LCLs. This study highlights that engineering EBV‐specific CTLs to express a higher level of mCD95L could represent an attractive therapeutic approach to improve T cell immunotherapy for PTLDs.